Amgen reported strong Q1 results with 7% revenue growth and 18% operating income growth, reaffirming full-year guidance. The positive reception of their pipeline developments, particularly evolocumab's promising data and imminent regulatory filings, signals potential for future growth. Despite minor inventory-related sales impacts, the company's solid financials and optimistic outlook suggest a positive short-term impact on the stock price.

[1]